Journal article
Germline BRCA variants, lifestyle and ovarian cancer survival
K Gersekowski, R Delahunty, K Alsop, EL Goode, JM Cunningham, SJ Winham, P Pharoah, H Song, S Jordan, S Fereday, A DeFazio, M Friedlander, A Obermair, PM Webb
Gynecologic Oncology | ACADEMIC PRESS INC ELSEVIER SCIENCE | Published : 2022
Abstract
Objective: Women with ovarian cancer who have a pathogenic germline variant in BRCA1 or BRCA2 (BRCA) have been shown to have better 5-year survival after diagnosis than women who are BRCA-wildtype (non-carriers). Modifiable lifestyle factors, including smoking, physical activity and body mass index (BMI) have previously been associated with ovarian cancer survival; however, it is unknown whether these associations differ by germline BRCA status. Methods: We investigated measures of lifestyle prior to diagnosis in two cohorts of Australian women with invasive epithelial ovarian cancer, using Cox proportional hazards regression to calculate adjusted hazard ratios (HRs) and 95% confidence inter..
View full abstractGrants
Awarded by Peter MacCallum Foundation
Funding Acknowledgements
OCAC Funding: The Ovarian Cancer Association Consortium is funded by the generous contributions of its research investigators. It has also been supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCI.07). The scientific development and funding for this project were in part supported by the US National Cancer Institute GAME-ON Post-GWAS Initiative (U19-CA148112). This study made use of data generated by the Wellcome Trust Case Control consortium that was funded by the Wellcome Trust under award 076113. Funding for individual studies: The OPAL Study was funded by the National Health and Medical Research Council (NHMRC) of Australia (GNT1025142, GNT1120431); blood collection was partly funded by a grant from the Brisbane Women's Club. The Australian Ovarian Cancer Study Groupwas supported by the U.S. ArmyMedical Research andMateriel Command (DAMD17-01-1-0729), National Health & Medical Research Council of Australia (199600, 400413 and 400281), Cancer Councils of New South Wales, Victoria, Queensland, South Australia and Tasmania and Cancer Foundation of Western Australia (MultiState Applications 191, 211 and 182). The Australian Ovarian Cancer Study gratefully acknowledges additional support from Ovarian Cancer Australia and the Peter MacCallum Foundation. Funding for BRCA testing was provided by the Australian Government (Public Health and Chronic Disease Grant Program), the US Department of Defense (W81XWH-08-1-0684 and W81XWH-08-1-0685), Cancer Australia (509303) and the Peter MacCallum Foundation. MAYO was funded by the National Institutes of Health (R01-CA122443, R01-CA248288, P50CA136393). SEARCH was funded by Cancer Research UK (C490/A10119 C490/A10124); UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge. University of Cambridge received salary support for PDPP from the NHS in the East of England through the Clinical Academic Reserve. PMWwas supported by an NHMRC Fellowship (GNT1173346).